Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Inserm Transfert Initiative is a seed stage life science vehicle currently managing about €4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2004 | Pharma Omnium | Series B | 2.4M |
10/2020 | VectivBio | Equity | 110M |
4/2016 | BIOMODEX | Seed Round | 3.6M |
7/2006 | ScreenCell | Seed Round | 3.2M |
11/2013 | Bioaxial | Seed Round | 2.7M |
1/2017 | Therachon | Series A | 5M |
6/2018 | BIOMODEX | Series A | 15M |
6/2018 | ENYO Pharma | Series B | 46.8M |
1/2015 | Sensorion | Venture Round | 4.6M |
9/2015 | Therachon | Series A | 35M |
8/2018 | Therachon | Series B | 60M |
4/2014 | AAVLife | Series A | 12M |
11/2017 | Step Pharma | Series A | 17M |
1/2020 | VectivBio | Series A | 35M |
12/2019 | Aelis Farma | Venture Round | 0 |
2/2009 | Hemarina | Series A | 1.1M |
1/2020 | Eyevensys | Series B | 30M |
12/2015 | Inception IBD | Series A | 14.1M |
7/2010 | Hemarina | Series B | 3.7M |
6/2015 | Eyevensys | Seed Round | - |
6/2008 | CellVir | Venture Round | 387k |
10/2020 | VectivBio | Venture Round | 0 |
1/2020 | Eyevensys | Series B | 0 |
1/2020 | VectivBio | Series A | 0 |
12/2019 | Aelis Farma | Venture Round | 0 |
8/2018 | Therachon | Series B | 0 |
6/2018 | BIOMODEX | Series A | 0 |
6/2018 | ENYO Pharma | Series B | 0 |
11/2017 | Step Pharma | Series A | 0 |
1/2017 | Therachon | Series A | 0 |
4/2016 | BIOMODEX | Seed Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|